Mahana Therapeutics
Developer of a digital brain–gut behavioral therapy program for people with diagnosed irritable bowel syndrome (IBS). The program delivers app-based gut-directed hypnotherapy, CBT-informed modules, and diaphragmatic breathing training, uses AI to personalize content and progression, has been evaluated in randomized and real-world studies, and expanded product assets via an acquisition announced May 8, 2025.
Industries
Nr. of Employees
small (1-50)
Mahana Therapeutics
Patents
Method and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using baseline physical activity data associated with the user
US-12073933-B2
View DetailsMethod and system for remotely monitoring the physical and psychological state of an application user using altitude and/or motion data and one or more machine learning models
US-11967432-B2
View DetailsMethod and system for remotely monitoring the psychological state of an application user using machine learning-based models
US-11684299-B2
View DetailsMethod and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using average physical activity data associated with a set of people other than the user
US-11610663-B2
View Details
Method and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using baseline physical activity data associated with the user
US-12073933-B2
View DetailsMethod and system for remotely monitoring the physical and psychological state of an application user using altitude and/or motion data and one or more machine learning models
US-11967432-B2
View DetailsMethod and system for remotely monitoring the psychological state of an application user using machine learning-based models
US-11684299-B2
View DetailsMethod and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using average physical activity data associated with a set of people other than the user
US-11610663-B2
View DetailsProducts
Structured digital gut-directed hypnotherapy program (six-week curriculum)
A protocol-driven digital behavioral program combining gut-directed hypnotherapy, CBT-informed modules, and breathing exercises delivered as daily audio sessions with on-demand tools and extended access.
Structured digital gut-directed hypnotherapy program (six-week curriculum)
A protocol-driven digital behavioral program combining gut-directed hypnotherapy, CBT-informed modules, and breathing exercises delivered as daily audio sessions with on-demand tools and extended access.
Services
Secure online referral intake and clinician dashboard that provides access to program structure, trial evidence, and patient progress reporting.
Application- and referral-based program offering automatic referral-based price adjustments and eligibility-based discounts up to full coverage to reduce out-of-pocket costs for annual program access.
Webinars, self-paced courses, downloadable guides, and on-demand materials for clinicians on integrating brain–gut behavioral therapies and selecting appropriate patients.
Secure online referral intake and clinician dashboard that provides access to program structure, trial evidence, and patient progress reporting.
Application- and referral-based program offering automatic referral-based price adjustments and eligibility-based discounts up to full coverage to reduce out-of-pocket costs for annual program access.
Webinars, self-paced courses, downloadable guides, and on-demand materials for clinicians on integrating brain–gut behavioral therapies and selecting appropriate patients.
Expertise Areas
- Digital therapeutics for disorders of gut–brain interaction
- App-based gut-directed hypnotherapy and CBT-informed interventions
- Clinical trial execution and real-world evidence generation
- Mechanistic physiology research in gut–brain interactions
Key Technologies
- AI-driven personalization
- Mobile (iOS/Android) and web application platforms
- Audio-based therapy delivery
- HIPAA-compliant referral and clinician dashboard systems
News & Updates
Peer-reviewed randomized controlled trial reporting program outcomes including reductions in abdominal pain and symptom severity versus an active control (American Journal of Gastroenterology).
Announcement of acquisition of digital therapy assets to expand therapeutic content and distribution (asset acquisition reported May 8, 2025).
Survey-based report summarizing lived experiences of over 3,000 individuals with IBS including diagnostic delays, gaps in discussion of the gut–brain connection, and uptake of psychological therapies.
Article describing a patient assistance program and reporting >50% reduction in self-reported IBS-related healthcare costs in a cohort from pre-program baseline to follow-up.
A randomized controlled trial published in The American Journal of Gastroenterology reported clinically significant improvements in IBS symptom severity and abdominal pain for the app-delivered program versus an active control.
Completed acquisition of digital therapeutic assets to expand content and reach (reported May 8, 2025).
Peer-reviewed randomized controlled trial reporting program outcomes including reductions in abdominal pain and symptom severity versus an active control (American Journal of Gastroenterology).
Announcement of acquisition of digital therapy assets to expand therapeutic content and distribution (asset acquisition reported May 8, 2025).
Survey-based report summarizing lived experiences of over 3,000 individuals with IBS including diagnostic delays, gaps in discussion of the gut–brain connection, and uptake of psychological therapies.
Article describing a patient assistance program and reporting >50% reduction in self-reported IBS-related healthcare costs in a cohort from pre-program baseline to follow-up.
A randomized controlled trial published in The American Journal of Gastroenterology reported clinically significant improvements in IBS symptom severity and abdominal pain for the app-delivered program versus an active control.
Completed acquisition of digital therapeutic assets to expand content and reach (reported May 8, 2025).